Medication and Personality Disorders

For many people with a personality disorder, the story goes like this. One medicine, then another, then a third added to the second. Each one was reasonable at the time. And the pattern that brought you in, the one in your relationships and your sense of self, keeps its shape.

That is not a failure of will, and it is usually not a failure of prescribing. It is what happens when a medicine is asked to do something no medicine has been shown to do. This article explains what a prescription can be aimed at, what the trials have found, and how to sit down with your prescriber and review the list.

Key takeaways

• As of September 7, 2026, a search of the FDA’s Drugs@FDA database found no medicine approved to treat a personality disorder itself. A medicine can only be aimed at something present and named, such as a co-occurring depression, never at the pattern.
• The 2022 Cochrane review of 46 trials and 2,769 participants found no reliable improvement in overall BPD severity, self-harm, suicide-related outcomes, or daily functioning from any medication class, with low certainty throughout.
• The American Psychiatric Association places medication in BPD as adjunctive to structured psychotherapy, aimed at a named target, with the list reviewed at least every six months.

Zoom

What a medicine can be aimed at

A forge does not create metal. The fire draws out only what is already in the ore. A medicine works the same way. It can act on something that is present and named: a major depressive episode, panic attacks, insomnia, ADHD, a substance-use disorder, a psychotic symptom. It cannot act on a personality pattern, because no medicine has been shown to change one.12

That is why a good medication target is narrower than the diagnosis on your chart. It is something you and your prescriber can both observe and check on a date: sleep, a depressive episode, panic, rage that follows a clear trigger. If the target is “borderline personality disorder” or “my personality,” there is no way to tell whether the medicine is working.12

Zero approved medicines, as of a date

On September 7, 2026, a search of the FDA’s Drugs@FDA label database found no approved indication for treating a personality disorder itself.56

Two things that sentence does not say. It does not say a medicine is never prescribed to someone with a personality disorder. Co-occurring conditions are common, and they are treated. And it does not say the answer is permanent. Labels change, which is why the date is attached and why the search is repeated before this page is updated.6

What the two major guidelines say

The American Psychiatric Association’s 2024 guideline for borderline personality disorder places medication as adjunctive to psychotherapy. Where a medicine is used, the guideline calls for a specific, measurable target, a time limit when the medicine is aimed at BPD symptoms, and medication review and reconciliation at least every six months.1

The United Kingdom’s NICE guideline, CG78, goes further. It advises against using medication specifically for BPD or for its individual symptoms, and it discourages medium- or long-term antipsychotic treatment for BPD. The guideline was published in 2009, was reviewed again in July 2024, and remains in force.2

The two guidelines differ in emphasis, not in facts. APA allows carefully targeted adjunctive use. NICE steers away from it. Both agree that structured psychotherapy comes first and that no medicine treats the disorder.12 One footnote: NICE states that it has not yet updated CG78 to the newer ICD-11 way of describing personality disorder, so its recommendations still speak the older diagnostic language.2

What the trials found

The broad review. The 2022 Cochrane review pooled 46 randomized trials with 2,769 participants, covering 29 medications over 4 to 52 weeks. It did not find reliable class-level improvement in overall BPD severity, self-harm, suicide-related outcomes, or psychosocial functioning. Most estimates were low or very low certainty, because the trials were small, short, at risk of bias, and poor at reporting side effects.3 A low-certainty signal for one symptom in one small trial is not evidence that the pattern itself is treatable.

The comorbidity gap. A 2025 analysis looked at 41 placebo-controlled BPD medication trials and asked a narrow question: did any of them select people who had BPD plus a confirmed co-occurring disorder, such as major depression? None did.4 That means the existing trials cannot tell you whether an antidepressant works for confirmed depression in someone who also has BPD. It does not mean antidepressants fail in that situation. That paper is sometimes misread as proof that they do. It is proof only that the right trial has not been run.4

Two recent drugs, tested in adults with BPD.

Brexpiprazole was tested in 80 adults over 12 weeks in a 2022 placebo-controlled trial. The overall result was marginal, and the separation from placebo came entirely from the final visit at week 12. Depression and anxiety measures did not differ.8 Then a larger trial, with 324 adults randomized across many sites, tested the same drug for the same indication. It did not meet its primary endpoint. The most common treatment-emergent side effect was akathisia, a restless inability to sit still, in 14.0 percent of people on brexpiprazole versus 1.2 percent on placebo.10 Read together, the two trials are one small late signal followed by a larger failed replication.

Lumateperone was tested in 60 adults over 8 weeks. The trial did not show a significant treatment difference on its main outcome or on secondary measures. More people on the active drug stopped early: 15 of 29 completed, compared with 23 of 31 on placebo.9

Neither drug is approved for BPD. Neither trial is a reason to ask for either one.8910

Why the list grows

A 2026 study of electronic health records followed adults with BPD who had been prescribed psychiatric medication across 15 U.S. states. Medication lists tended to grow over time.7 The study has real limits: only a small fraction of the starting group had a full year of follow-up, it did not measure whether people took the medicines or whether they were in psychotherapy, and its authors work for companies with an interest in the data. For those reasons this page does not quote its percentage as a general rate.7

The direction is still worth knowing. Lists grow when each new medicine is added for a reason that was never written down as a target, so nothing ever gets removed.

How to hold a medication review

This is a conversation guide, not an instruction to change anything. Bring it to the prescriber who manages your medicines. For each medicine on your list, ask four questions together.12

If a medicine has no clear target, or its target has resolved, that is worth naming out loud. Any change should then be collaborative, individualized, monitored, and made one medicine at a time when the clinician judges that appropriate.12 Stopping on your own can cause withdrawal, relapse of the condition the medicine was treating, or interactions with the medicines that remain. This article gives no taper schedule, because there is no single safe one.

When to get help sooner

Get urgent help for suicidal intent, a plan with access, or an inability to stay safe. Get urgent help for an overdose, a severe reaction to a medicine, psychosis, mania, or severe intoxication or withdrawal. Call or text 988 in the United States for suicide or emotional crisis. Call 911 or go to the nearest emergency department for immediate danger.

What to do next

Print your current medication list. Next to each medicine, write the target and the review date, or write “unknown.” Bring the sheet to your next appointment. The unknowns are the conversation.

Frequently asked questions

Is there a medicine for borderline personality disorder?

No medicine is FDA-approved for a personality disorder itself as of September 7, 2026. The 2022 Cochrane review of 46 trials found no reliable medication benefit for BPD severity, self-harm, or functioning.

Then why am I on three medicines?

Often because each one was added for a co-occurring condition or a symptom without a written target or review date. A medication review with your prescriber is the place to sort that out. Do not stop anything on your own.

Do antidepressants work if I have depression and BPD?

The existing BPD trials never selected people with confirmed depression, so they cannot answer that question. They also do not show that antidepressants fail. Your prescriber treats the depression that is present.

Are the new antipsychotic trials good news?

No. Brexpiprazole showed a marginal late signal in 80 adults and then missed its primary endpoint in 324, with akathisia in 14.0 percent versus 1.2 percent on placebo. Lumateperone showed no benefit in 60 adults over 8 weeks.

How often should my medicines be reviewed?

The American Psychiatric Association guideline for BPD calls for review and reconciliation at least every six months, with a named target for each medicine.

This article is for education, not personal medical advice. Do not start, stop, restart, or change a medication without the clinician who manages it. Every numeric, regulatory, and citation claim was verified against primary journal, federal, and labeling sources on September 7, 2026. Guidelines, drug labels, and trial records change; confirm current status before acting on anything here.

Related reading on NP FADY

• What DBT Actually Is and How to Find It
• When Full DBT Is Out of Reach
• Borderline Personality Disorder: Beyond the Stigma
• Rexulti (Brexpiprazole): What It Treats, Its Side Effects, and How It Compares With Abilify
• What Personality-Disorder Recovery Really Looks Like

References

1. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder, Second Edition. Washington, DC: American Psychiatric Association Publishing; 2024. DOI: 10.1176/appi.books.9780890428009. Medication adjunctive to psychotherapy; review and reconciliation at least every six months. Guideline.

2. National Institute for Health and Care Excellence. “Borderline personality disorder: recognition and management. Clinical guideline CG78.” Published 2009; last reviewed July 30, 2024; accessed September 7, 2026. NICE CG78.

3. Stoffers-Winterling JM, Storebø OJ, Kongerslev MT, et al. “Pharmacological interventions for people with borderline personality disorder.” Cochrane Database of Systematic Reviews. 2022;11(11):CD012956. DOI: 10.1002/14651858.CD012956.pub2. PMID: 36375174. 46 trials, 2,769 participants, 29 medications. PubMed.

4. Pereira Ribeiro J, Arendt Nielsen T, Kongerslev MT, et al. “Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analyses of a systematic review.” British Journal of Psychiatry. 2025;226(4):226–237. DOI: 10.1192/bjp.2024.172. 41 placebo-controlled trials; none selected participants for BPD plus a confirmed co-occurring disorder. Cambridge Core.

5. American Psychiatric Association. “What are personality disorders?” Physician review November 2024; accessed September 7, 2026. APA.

6. U.S. Food and Drug Administration. “Drugs@FDA: FDA-Approved Drugs.” Label database searched September 7, 2026. Drugs@FDA.

7. White C, et al. “Treatment trajectories of patients with borderline personality disorder prescribed pharmacotherapy: real-world insights from a retrospective observational study.” BMC Psychiatry. 2026;26(1):351. DOI: 10.1186/s12888-026-07974-6. PMID: 41862841. Retrospective cohort, 15 U.S. states; authors employed by Boehringer Ingelheim and Holmusk. PubMed.

8. Grant JE, Valle S, Chesivoir E, Ehsan D, Chamberlain SR. “A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder.” British Journal of Psychiatry. 2022;220(2):58–63. DOI: 10.1192/bjp.2021.159. PMID: 35049469. N = 80, 12 weeks; NCT03418675. PubMed.

9. Grant JE, Boutouis S, Avila L, Neelapu M, Ehsan D. “A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.” Clinical Neuropharmacology. Published online June 15, 2026. DOI: 10.1097/WNF.0000000000000693. PMID: 42384092. N = 60, 8 weeks; NCT05356013; funded by Intra-Cellular Therapies. PubMed.

10. Rothman B, Brewer C, Chang D, Hobart M, Hefting N, McQuade RD, Grant JE. “A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder.” Acta Neuropsychiatrica. 2024;37:e39. DOI: 10.1017/neu.2024.31. PMID: 39558901. N = 324; primary endpoint not met (p = 0.24); akathisia 14.0 percent versus 1.2 percent; NCT04100096 and NCT04186403; funded by Otsuka and Lundbeck. PubMed.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.